Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloabiatlve allogeneic transplantation

Haematologica

Volumn 90, Issue 2, 2005, Pages 278-279

  Patriarca, Francesca ^a,c   Prosdocimo, Simonetta ^a   Tomadini, Valentina ^a   Vasciaveo, Annarosa ^a   Bruno, Benedetto ^b   Fanin, Renato ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Bortezomib; Extramedullary relapse; Multiple myeloma

Indexed keywords

BORTEZOMIB; CORTICOSTEROID; CYCLOSPORIN A; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; VINCRISTINE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CRANIAL NERVE PARALYSIS; DRUG MEGADOSE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMAGE ENHANCEMENT; MULTIPLE MYELOMA; NONMYELOABLATIVE CONDITIONING; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; SPINAL CORD COMPRESSION; SPINE CANCER; THORAX TUMOR; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ANTINEOPLASTIC AGENTS; BIOPSY; BORONIC ACIDS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; PROTEASE INHIBITORS; PYRAZINES; RECURRENCE; TOMOGRAPHY, X-RAY COMPUTED; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 14344262210     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Alegre A, Granda A, Martinez-Chamorro C, Diaz-Mediavilla J, Martinez R, Garcia-Larana J, et al. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry. Haematologica 2002;87:609-14.
2. Biagi JJ, Mileshkin L, Grigg AP, Westerman DW, Prince HM. Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation. Bone Marrow Transplant 2001;28:1145-50.
3. Veisten A, Brizard A, Randriamalata E, Babin P, Preud'homme JI, Guilhot F. Central nervous system relapses after autologous stem cell transplantation for myeloma. Report of two cases. Haematol Cell Ther 1997;39:327-30.
4. Patriarca F, Zaja F, Silvestri F, Sperotto A, Scalise A, Gigli G, et al. Meningeal and cerebral involvement in multiple myeloma patients. Ann Hematol 2001;80:758-62.
5. Fassas AB, Muwalla F, Berryman T, Benramdane R, Joseph L, Anaissie E, et al. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol 2002;117:103-8.
6. Petersen SL, Wagner A, Gimsing P. Cerebral and meningeal multiple myeloma after autologous stem cell transplantation. A case report and review of the literature. Am J Hematol 1999; 62:228-33.
7. Rosinol L, Cibeira MT, Bladè J, Esteve J, Aymerich M, Rozman M, et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica 2004;89:832-6.
8. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase II study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
9. Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003;8:508-13.
10. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 2004;22:304-6.